{ "docId": "019dd923-622c-750b-8b9a-3bcd52c6e583", "docSlug": "f06b0b5d2079", "documentTitle": "Soleno Therapeutics (SLNO)", "authorId": "58_Scorpion_Capital", "authorName": "Scorpion Capital", "documentKindSlug": "activist-deck", "documentKindLabel": "Activist deck", "sourceTypeSlug": "short_seller", "sourceTypeLabel": "Short seller", "presentationDate": "2025-08-15 00:00:00", "orientation": "landscape", "aspectRatio": 1.3333334, "pageNumber": 335, "pageCount": 415, "prevPage": 334, "nextPage": 336, "slideType": "expose_contradiction", "function": "expose_contradiction", "density": "overcrowded", "nDataPoints": 3, "notes": "The slide uses direct quotes from an interview to highlight the discrepancy between public promotion and private clinical reality.", "elementsJson": [ "paragraph", "quote_block", "footnote" ], "metadataConfidence": 1, "imagePath": null, "slideHref": "/slides/019dd923-622c-750b-8b9a-3bcd52c6e583/335", "deckHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583", "deckJsonHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583.json", "deckAnchorHref": "/decks/019dd923-622c-750b-8b9a-3bcd52c6e583#slide-335", "components": [ { "bbox": null, "kind": "callout", "text": "However, the investigator's private, critical commentary casts doubt on the integrity of the public posturing – almost all Vykat patients have discontinued the drug due to \"drug reaction,\" \"side effects,\" or \"didn't want to be in the trial anymore.\"", "attrs": null, "subkind": null, "toolName": "Visual emphasis", "toolSlug": "visual-emphasis", "confidence": null, "componentId": "019dd953-64ce-7561-b2b3-bef5c2a7a38f", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.41 }, "kind": "paragraph", "text": "Pediatric endocrinologist with 35 PWS patients; also works with adult PWS clinic with 60-70 patients", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "995a5d25-080f-4414-899a-96793c1c6c64", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.04, "w": 0.86, "x": 0.07, "y": 0.56 }, "kind": "paragraph", "text": "Almost all patients out of approximately 10 discontinued due to “drug reaction,” “side effects,” or just didn’t want to be on drug", "attrs": null, "subkind": "paragraph", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "b63123e7-2b91-42e9-8b59-398167ae0f30", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.08, "w": 0.86, "x": 0.07, "y": 0.45 }, "kind": "quote", "text": "“I'm a pediatric endocrinologist, so I only see children up until the age of 18. And I've got 35 patients in my caseload. And when patients are 18, I'll refer to an adult endocrinologist, and he looks after approximately 60 or maybe 70 patients with Prader-Willi Syndrome...we see our patients every four months, sometimes every five months, but ideally every four months. In a lot of other places, they're being seen only once a year.” -Trial investigator/author, pediatric endocrinologist", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "9a1d3410-a620-4443-a73d-a83b42220119", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.18, "w": 0.86, "x": 0.07, "y": 0.6 }, "kind": "quote", "text": "Q: “How many patients did you enroll in the Vykat trials, starting with maybe the Phase 3?”\nA: “And so, we had [slightly under 10] patients actively running. And I think we screened two more patients that then didn't fulfill criteria.”\nQ: “And then how many of them are still on it?”\nA: “And so, in the moment in my clinic, there are still two on it...one patient stopped because of drug reaction. One patient stopped because they didn't want to be in the trial anymore...one patient was transferred to adult, started working, so also didn't want to be involved anymore. One patient felt that they had side effects...and therefore didn't want to continue. I think that's probably it.” - Trial investigator/author, pediatric endocrinologist", "attrs": null, "subkind": "testimonial", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "c059260d-5110-47ab-bce7-6462166d3b59", "frameworkName": null, "frameworkSlug": null }, { "bbox": null, "kind": "quote", "text": "\"I'm a pediatric endocrinologist, so I only see children up until the age of 18. And I've got 35 patients in my caseload. And when patients are 18, I'll refer to an adult endocrinologist, and he looks after approximately 60 or maybe 70 patients with Prader-Willi Syndrome...we see our patients every four months, sometimes every five months, but ideally every four months. In a lot of other places, they're being seen only once a year.\" — Trial investigator/author, pediatric endocrinologist; \"And so, we had [slightly under 10] patients actively running. And I think we screened two more patients that then didn't fulfill criteria.\" — Trial investigator/author, pediatric endocrinologist; \"And so, in the moment in my clinic, there are still two on it...one patient stopped because of drug reaction. One patient stopped because they didn't want to be in the trial anymore...one patient was transferred to adult, started working, so also didn't want to be involved anymore. One patient felt that they had side effects...and therefore didn't want to continue. I think that's probably it.\" — Trial investigator/author, pediatric endocrinologist", "attrs": null, "subkind": null, "toolName": "Authority citation", "toolSlug": "authority-citation", "confidence": null, "componentId": "019dd953-64ce-7561-b2b3-c0b4160753e0", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.02, "w": 0.25, "x": 0.07, "y": 0.95 }, "kind": "source-note", "text": "Source: Scorpion Capital consultation calls with experts", "attrs": null, "subkind": null, "toolName": null, "toolSlug": null, "confidence": null, "componentId": "fec97cb4-1f06-4ac2-893b-a4a123c5f7c2", "frameworkName": null, "frameworkSlug": null }, { "bbox": { "h": 0.25, "w": 0.86, "x": 0.07, "y": 0.07 }, "kind": "title", "text": "Trial investigator #8: Not considered a KOL or published authority on PWS, but was a key investigator and author for Soleno across the phase 3, open-label, and withdrawal study, with a caseload of 35 PWS patients and around 10 patients enrolled in the trials. The investigator is publicly promotional on Soleno’s behalf, and was defensive during our interview and bristled at our questions. However, the investigator’s private, critical commentary casts doubt on the integrity of the public posturing – almost all Vykat patients have discontinued the drug due to “drug reaction,” “side effects,” or “didn’t want to be in the trial anymore.”", "attrs": null, "subkind": "headline", "toolName": null, "toolSlug": null, "confidence": null, "componentId": "53893de9-0a57-4ab3-af11-02ff2ec7152c", "frameworkName": null, "frameworkSlug": null } ], "metrics": [], "tools": [], "frameworks": [ { "name": "ceo-quote-contradiction", "slug": null, "matchId": "02b2b07d-add8-409a-b2a5-f18fc07afd3a", "evidence": "The slide explicitly contrasts public promotional behavior with private critical commentary.", "confidence": 0.9 } ], "arcBeats": [], "loops": [], "imagePathAlt": null, "thumbSrc": null, "thumbSrcAlt": null, "locked": true }